Clinical trials: Hypertension, Pulmonary Artery
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with…
- Trial name
- PAH (NCT01457781)
- Testing
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Where
- 51 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
The purpose of this study is to assess the effect of BIA 5-1058 200 mg on the pharmacokinetic (PK) of treprostinil
- Trial name
- NCT04675944
- Testing
- BIA 5-1058, treprostinil
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
The investigators aim to study the effect of SOT in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
- Conditions
- Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- NCT06384534
- Testing
- 6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)
- Trial name
- CPETPH (NCT02061787)
- Testing
- balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Hypertension
Acute Exposure to High Altitude on Blood and Tissue Oxygenation (ABGA, NIRS)
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) on blood and tissue oxygenation (ABGA, NIRS).
- Trial name
- NCT03600415
- Testing
- Low altitude: 470m above sea level, Säntis; 2500m above sea level
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension
Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)
Treatment of PAH includes exercise limitation, non specific agents (anticoagulants, diuretics and supplemental oxygen), pulmonary specific vasodilators and antiproliferative agents.
- Trial name
- MetHTAP (NCT01352026)
- Testing
- Metformin
- Where
- 2 sites in France
- Sponsor
- Nantes University Hospital
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension
The goal of this clinical study is to investigate whether the additional intake of sildenafil 20mg on top of standard medical treatment results in a benefit on maximum exercise workload (Wmax) in patients with pulmonary arterial…
- Trial name
- Pocket-PH (NCT07824674)
- Testing
- Dextrose, Sildenafil 20mg
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich
Pulmonary Arterial Hypertension
Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension.
- Trial name
- NCT04104490
- Where
- 2 sites in United States, Brazil
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Florida
Hypertension, Pulmonary
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies [NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177…
- Trial name
- PLATYPUS (NCT05179876)
- Testing
- Macitentan, Selexipag, Macitentan/Tadalafil FDC
- Where
- 45 sites in Belarus, Belgium and 11 more
- Volunteers
- 280 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Exercise Capacity Respiratory Muscle Strength Dyspnea and Physical Activity in Pediatric Pulmonary Arterial Hypertension
The primary aim of this study was to evaluate exercise capacity, respiratory muscle strength, pulmonary function, dyspnea and physical activity levels in pediatric PAH patients and compare them with healthy controls.
- Trial name
- NCT05124015
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Gazi University